The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice

Adam L Hartman1, Polan Santos, Alison Dolce

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America. Ahartma2@jhmi.edu

Plos One
|September 18, 2012
PubMed
Abstract

Insights

Rapamycin, an mTOR inhibitor, shows limited acute anticonvulsant effects in mice, offering some protection against specific seizure types but not others. Its efficacy as an acute seizure treatment may be restricted.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • The mammalian target of rapamycin (mTOR) pathway regulates cellular responses to nutrients.
  • mTOR inhibitors like rapamycin show promise in chronic epilepsy models and tuberous sclerosis patients.
  • The acute anticonvulsant effects of mTOR inhibitors remain largely unexplored.

Purpose of the Study:

  • To investigate the acute anticonvulsant activity of rapamycin in mice.
  • To determine if rapamycin exhibits short-term seizure suppression.
  • To compare rapamycin's acute effects with its known longer-term antiepileptogenic properties.

Main Methods:

  • Acute seizure susceptibility tests were performed on mice following single or multiple intraperitoneal injections of rapamycin.
  • Mice were evaluated using standard seizure tests, including MES, 6 Hz, and PTZ, within 6 hours or after 3+ daily doses.
  • The study assessed both short-term and longer-term effects of rapamycin on seizure thresholds and activity.

Main Results:

  • Short-term rapamycin treatment provided limited protection against tonic hindlimb extension in the MES test, with waning efficacy over time.
  • Longer-term rapamycin treatment showed protection against kainic acid-induced seizures, but only at delayed time points.
  • Rapamycin did not demonstrate protective effects in the 6 Hz or PTZ seizure tests under either short-term or longer-term treatment conditions.

Conclusions:

  • Rapamycin exhibits limited efficacy as an acute anticonvulsant in normal mice.
  • The anticonvulsant profile of rapamycin distinguishes it from fasting and ketogenic diets, aligning more closely with sodium channel blockers.
  • Further research is needed to fully elucidate the role of mTOR inhibition in acute seizure management.